Neumora Therapeutics is expected to report a Q2 2026 loss of $0.23 per share on zero revenue, with its current stock price of $1.64 trading significantly below the average analyst price target of $6.57. Investors are primarily focused on the company's revised business strategy and pipeline prioritization following the devastating failure of its lead candidate, navacaprant, in Phase 3 depression trials in June 2026.
The discontinuation of the navacaprant program led to an immediate 35% reduction in workforce to preserve capital and extend the company's cash runway. Management is now pivoting focus toward NMRA-511 for Alzheimer’s disease agitation and NMRA-898 for schizophrenia, with clinical updates for both programs anticipated in the second half of 2026. Analysts will be scrutinizing the updated cash burn rates to confirm if the current liquidity remains sufficient to fund operations into the third quarter of 2027 as previously guided.